The key risks across both compounds include: Gastrointestinal adverse events (nausea, vomiting, diarrhoea), most pronounced during dose escalation Potential for gallbladder disease, consistent with rapid weight reduction Retatrutide-specific: dysesthesia and elevated resting heart rate [3] Both compounds: risk of hypoglycaemia when used in combination with insulin or sulphonylureas in diabetic models All compounds available through Sempica are strictly for research use by qualified professionals
Tirzepatide is supplied in single-dose prefilled pens with a hidden needle designed for subcutaneous injection
Your body doesnt work quite as efficiently behind the scenes, which can leave you feeling foggy, worn out, or just not like yourself
It matches the route used in all clinical trials that established tirzepatide efficacy and safety data
Monitoring and Communication Keep a symptom diary noting bowel movement frequency, consistency, and any associated symptoms